Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Jan 21, 2014; 20(3): 795-803
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.795
Published online Jan 21, 2014. doi: 10.3748/wjg.v20.i3.795
Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines
Daniele Baiz, Barbara Dapas, Bruna Scaggiante, Sara Chiaretti, Gabriele Grassi, Department of Life Sciences, University of Trieste, 34100 Trieste, Italy
Daniele Baiz, Wake Forest School of Medicine, Department of Cancer Biology and Comprehensive Cancer Center, Medical Center Boulevard, Winston Salem, NC 27157, United States
Rossella Farra, Department of Industrial Engineering and Information Technology, University of Trieste, 34100 Trieste, Italy
Gabriele Pozzato, Fabrizio Zanconati, Nicola Fiotti, Lara Consoloni, Gabriele Grassi, Department of ‘‘Scienze Mediche, Chirurgiche e della Salute’’, University of Trieste, Cattinara Hospital, 34100 Trieste, Italy
Author contributions: Baiz D performed the research; Dapas B, Farra R and Consoloni L performed the research; Scaggiante B, Pozzato G, Zanconati F, Fiotti N and Grassi G designed the research and wrote the paper; Chiaretti S analyzed the data.
Supported by The “Fondazione Cassa di Risparmio of Trieste; the “Fondazione Benefica Kathleen Foreman Casali of Trieste”; the Italian Minister of Instruction, University and Research (MIUR), PRIN 2010-11, No. 20109PLMH2 (in part)
Correspondence to: Gabriele Grassi, MD, PhD, Department of Life Sciences, University Hospital of Cattinara, Strada di Fiume 447, 34100 Trieste, Italy. ggrassi@units.it
Telephone: 39-40-3996227 Fax: +39-40-3994593
Received: June 29, 2013
Revised: November 11, 2013
Accepted: December 3, 2013
Published online: January 21, 2014
Processing time: 235 Days and 23.6 Hours
Revised: November 11, 2013
Accepted: December 3, 2013
Published online: January 21, 2014
Processing time: 235 Days and 23.6 Hours
Core Tip
Core tip: The 26S proteasome inhibitor bortezomib has been proposed as a novel therapeutic molecule for hepatocellular carcinoma (HCC), being able to reduce cell growth. Little information is available on the effect of bortezomib (BZB) on many of E2Fs, a family of transcription factors regulating normal and tumor cell proliferation. Our data show, for the first time, the BZB effect on expression of E2F family members in HCC cell lines is not limited to the most studied E2F1, but, it extends also to other E2F members, in particular E2F2, E2F8 and E2F6, and the effect is phenotypic dependent.